x NoneEntity Type
0001469443
 
x Corporation
o Limited Partnership
o Limited Liability Company
o General Partnership
o Business Trust
o Other
Name of Issuer
 Arcadia Biosciences, Inc.
Jurisdiction of Incorporation/OrganizationDELAWARE 
Year of Incorporation/Organization
  x Over Five Years Ago
  o Within Last Five Years (Specify Year)  
  o Yet to Be Formed 



2. Principal Place of Business and Contact Information
Name of Issuer 
 Arcadia Biosciences, Inc. 
Street Address 1Street Address 2
 202 COUSTEAU PLACE SUITE 105
CityState/Province/CountryZIP/Postal CodePhone No. of Issuer
 DAVIS UNITED STATES 95618 602-429-0471 



3. Related Persons
Last NameFirst NameMiddle Name
PlavanMatthewT
Street Address 1Street Address 2
202 Cousteau Place, Suite 105
CityState/Province/CountryZIP/Postal Code
DavisCALIFORNIA95618
Relationship: x Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
HaleyPam
Street Address 1Street Address 2
202 Cousteau Place, Suite 105
CityState/Province/CountryZIP/Postal Code
DavisCALIFORNIA95618
Relationship: x Executive Officer o Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
ComcowichKevin
Street Address 1Street Address 2
202 Cousteau Place, Suite 105
CityState/Province/CountryZIP/Postal Code
DavisCALIFORNIA95618
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
BollesAlbertD
Street Address 1Street Address 2
202 Cousteau Place, Suite 105
CityState/Province/CountryZIP/Postal Code
DavisCALIFORNIA95618
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

 
Last NameFirst NameMiddle Name
MurrayLilianShackelford
Street Address 1Street Address 2
202 Cousteau Place, Suite 105
CityState/Province/CountryZIP/Postal Code
DavisCALIFORNIA95618
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
WallerGregoryD
Street Address 1Street Address 2
202 Cousteau Place, Suite 105
CityState/Province/CountryZIP/Postal Code
DavisCALIFORNIA95618
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
YoderAmy
Street Address 1Street Address 2
202 Cousteau Place, Suite 105
CityState/Province/CountryZIP/Postal Code
DavisCALIFORNIA95618
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

 


4. Industry Group
o Agriculture Health Care o Retailing
 Banking & Financial Services   o Biotechnology o Restaurants
  o Commercial Banking   o Health Insurance Technology
  o Insurance  o Hospitals & Physicians  o Computers
  o Investing  o Pharmaceuticals  o Telecommunications
  o Investment Banking  o Other Health Care  x Other Technology
  o Pooled Investment Fund

    Travel
  o Other Banking & Financial Services o Manufacturing  o Airlines & Airports
 Real Estate  o Lodging & Conventions
  o Commercial  o Tourism & Travel Services
  o Construction  o Other Travel
  o REITS & Finance o Other
  o Residential 
  o Other Real Estate 
o Business Services 
 Energy 
  o Coal Mining 
  o Electric Utilities 
  o Energy Conservation 
  o Environmental Services 
  o Oil & Gas 
  o Other Energy 


5. Issuer Size
Revenue RangeAggregate Net Asset Value Range
o No Revenues o No Aggregate Net Asset Value
o $1 - $1,000,000 o $1 - $5,000,000
o $1,000,001 - $5,000,000 o $5,000,001 - $25,000,000
o $5,000,001 - $25,000,000 o $25,000,001 - $50,000,000
o $25,000,001 - $100,000,000 o $50,000,001 - $100,000,000
o Over $100,000,000 o Over $100,000,000
x Decline to Disclose o Decline to Disclose
o Not Applicable o Not Applicable


6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)
o Rule 504(b)(1) (not (i), (ii) or (iii)) o Rule 505
o Rule 504 (b)(1)(i) x Rule 506(b)
o Rule 504 (b)(1)(ii) o Rule 506(c)
o Rule 504 (b)(1)(iii) o Securities Act Section 4(a)(5)
  o Investment Company Act Section 3(c)

7. Type of Filing
x New Notice Date of First Sale 2021-01-28 o First Sale Yet to Occur
o Amendment

8. Duration of Offering
Does the Issuer intend this offering to last more than one year? o Yes x No

9. Type(s) of Securities Offered (select all that apply)
o Pooled Investment Fund Interests x Equity
o Tenant-in-Common Securities o Debt
o Mineral Property Securities x Option, Warrant or Other Right to Acquire Another Security
o Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security x Other (describe)
 Common stock and warrants to purchase common stock


10. Business Combination Transaction
Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? o Yes x No
 
Clarification of Response (if Necessary) 
  

11. Minimum Investment
Minimum investment accepted from any outside investor$ 0 USD

12. Sales Compensation
RecipientRecipient CRD Number o None
 H.C. Wainwright & Co., LLC 375
(Associated) Broker or Dealer o None(Associated) Broker or Dealer CRD Number o None
 H.C. Wainwright & Co., LLC 375
Street Address 1Street Address 2
 430 Park Avenue  
City State/Province/CountryZIP/Postal Code
 New York NEW YORK 10022
State(s) of Solicitation o All States o Foreign/Non-US
 CONNECTICUT
 NEW JERSEY
 NEW YORK
 

 



13. Offering and Sales Amounts
Total Offering Amount $ 25000000 USD o Indefinite
Total Amount Sold $ 25000000 USD 
Total Remaining to be Sold $ 0 USD o Indefinite
 
Clarification of Response (if Necessary)
  


14. Investors
o Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,
Number of such non-accredited investors who already have invested in the offering
 
  Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering: 26


15. Sales Commissions & Finders’ Fees Expenses
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
Sales Commissions$ 1750000 USD o Estimate
Finders' Fees$ 0 USD o Estimate
 
Clarification of Response (if Necessary)
  


16. Use of Proceeds
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
 $ 0 USD o
Arcadia Biosciences (NASDAQ:RKDA)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Arcadia Biosciences Charts.
Arcadia Biosciences (NASDAQ:RKDA)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Arcadia Biosciences Charts.

Arcadia Biosciences, Inc. News

Arcadia Biosciences (RKDA) Announces Date of First Quarter 2024 Financial Results and Business Highlights Conference Call
Thursday 25 April 2024 (6 days ago) • Business Wire
Arcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2023 Financial Results and Business Highlights
Friday 29 March 2024 (1 month ago) • Business Wire
Arcadia Biosciences (RKDA) Announces Date of Fourth Quarter 2023 Financial Results and Business Highlights Conference Call
Thursday 14 March 2024 (2 months ago) • Business Wire
Arcadia Biosciences (RKDA) Expands GoodWheat™ Mac & Cheese with Nationwide Availability
Wednesday 21 February 2024 (2 months ago) • Business Wire
Form 8-K - Current report
Thursday 15 February 2024 (3 months ago) • Edgar (US Regulatory)
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Thursday 15 February 2024 (3 months ago) • Edgar (US Regulatory)
Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 6 February 2024 (3 months ago) • Edgar (US Regulatory)
Form SC 13G - Statement of acquisition of beneficial ownership by individuals
Thursday 4 January 2024 (4 months ago) • Edgar (US Regulatory)
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Friday 10 November 2023 (6 months ago) • Edgar (US Regulatory)
Form 8-K - Current report
Friday 10 November 2023 (6 months ago) • Edgar (US Regulatory)
Arcadia Biosciences (RKDA) Announces Strong Third Quarter 2023 Financial Results and Business Highlights
Friday 10 November 2023 (6 months ago) • Business Wire
Arcadia Biosciences (RKDA) Announces Date of Third Quarter 2023 Financial Results and Business Highlights Conference Call
Thursday 26 October 2023 (6 months ago) • Business Wire

More Arcadia Biosciences, Inc. News Articles